To test the long‐term (10 days) effects of the AMG510 and IN10018 drug combination, we performed cell colony formation assays with diverse KRAS mutant cancer, using specific doses of each combination therapy agent (based on individually testing AMG510 and IN10018 for each cell line). The gene discussed is KRAS; the disease is cancer.